Fibrin glue vasodilation agent sustained-release long-acting composition

A vasodilator and fibrin glue technology, which is applied in the field of fibrin glue vasodilator sustained-release long-acting compositions, can solve the problem that the blood drug concentration of bypass spasm cannot be reached, reduce the dosage of calcium ion antagonist, and limit calcium ion antagonism. It can reduce the pain of skin and flesh, have no toxic and side effects, and achieve the effect of good histocompatibility.

Inactive Publication Date: 2010-12-15
PEKING UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, calcium antagonists cannot be used immediately after the operation, because it will cause a decrease in myocardial contractility, resulting in a decrease in postoperative cardiac output, affecting the perfusion of tissues and organs throughout the body, and causing hypotension, sinus bradycardia, and heart failure failure, etc.
It has been reported in the literature that about 20% of patients after surgery cannot tolerate the above adverse reactions after using calcium antagonists
If the dosage of calcium antagonists is reduced on the premise of not affecting circulatory stability, the blood drug concentration that is effective against bypass spasm is often not achieved
These will limit the use of calcium antagonists in the early postoperative period

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fibrin glue vasodilation agent sustained-release long-acting composition
  • Fibrin glue vasodilation agent sustained-release long-acting composition
  • Fibrin glue vasodilation agent sustained-release long-acting composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] A fibrin glue vasodilator slow-release long-acting composition capable of preventing and inhibiting post-coronary artery bypass grafting spasm, which is compounded by fibrin glue and vasodilator papaverine hydrochloride, and its compound ratio is 1 Milliliter: 1 mg.

[0027] among them:

[0028] Fibrin glue is a hemostatic agent composed of mammalian fibrinogen, human thrombin, fibrinolytic inhibitor and calcium chloride that has been treated with virus inactivation. In order to simulate the final stage reaction of blood coagulation, thrombin is used to activate fibrinogen to form fibrin, which adheres to the wound, has hemostasis and promotes healing.

[0029] Can be configured and used on site. When using, the first choice is to dissolve papaverine hydrochloride with component II, which is the main body glue diluent, and then dilute the main body glue (component I) with the main body glue diluent containing papaverine hydrochloride according to the operating specifications...

Embodiment 2

[0032] A fibrin glue vasodilator slow-release long-acting composition capable of preventing and inhibiting post-coronary artery bypass grafting spasm, which is compounded by fibrin glue and vasodilator papaverine hydrochloride, and its compound ratio is 1 Milliliter: 3 mg.

[0033] among them:

[0034] Fibrin glue is a hemostatic agent composed of mammalian fibrinogen, human thrombin, fibrinolytic inhibitor and calcium chloride that has been treated with virus inactivation. In order to simulate the final stage reaction of blood coagulation, thrombin is used to activate fibrinogen to form fibrin, which adheres to the wound, has hemostasis and promotes healing.

[0035] Can be configured and used on site. When using, the first choice is to dissolve papaverine hydrochloride with component II, which is the main body glue diluent, and then dilute the main body glue (component I) with the main body glue diluent containing papaverine hydrochloride according to the operating specifications...

Embodiment 3

[0038] A fibrin glue vasodilator slow-release long-acting composition capable of preventing and inhibiting post-coronary artery bypass grafting spasm, which is compounded by fibrin glue and vasodilator papaverine hydrochloride, and its compound ratio is 1 Milliliter: 10 mg.

[0039] among them:

[0040] Fibrin glue is a hemostatic agent composed of mammalian fibrinogen, human thrombin, fibrinolytic inhibitor and calcium chloride that has been treated with virus inactivation. In order to simulate the final stage reaction of blood coagulation, thrombin is used to activate fibrinogen to form fibrin, which adheres to the wound, has hemostasis and promotes healing.

[0041] Can be configured and used on site. When using, the first choice is to dissolve papaverine hydrochloride with component II, which is the main body glue diluent, and then dilute the main body glue (component I) with the main body glue diluent containing papaverine hydrochloride according to the operating specification...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a long acting composition of the fibrin glue vasodilating agent with sustained release property, which comprises a vasodilating agent and a spasmolysant of effective amount, fibrin glue that can delay the releasing of the vasodilating agent. The present invention is characterized in that the composition is a mixture of the fibrin glue and the vasodilating agent; the mixing concentration changes in the range from 0.1mg per ml to 10mg per ml according to various kinds of vasodilating agents. In the present invention, the long acting composition of the fibrin glue vasodilating agent with sustained release property has the following properties of good tissue compatibility, slow releasing of the drugs, long maintenance in the application area and reduction of the side effects to the human body. The present invention is applied in the control during surgery as well as the prevention and treatment after the surgery, which can cause the vasospasm attack. The present invention is particularly applied in the prevention and reduction of the convulsive seizure, which occurs in the coronary artery bypass grafting operation or after the operation. Therefore the pain of the patient is dramatically decreased and the cure rate is improved, and the recurrence is reduced.

Description

Technical field [0001] The invention relates to a sustained-release and long-acting composition of a fibrin glue vasodilator. Specifically, it relates to a composition containing fibrin glue and an effective amount of a vasodilator or antispasmodic for dilating blood vessels to avoid spasm and can maintain a longer effective time of action. technical background [0002] Coronary atherosclerotic heart disease (coronary heart disease) is a global problem. With the aging trend of the population and the changes in people's lifestyle and quality of life, coronary heart disease has gradually become a major disease threatening global health. At present, for most patients with coronary heart disease, early coronary artery bypass graft (CABG) surgery is the best treatment method, which can significantly improve the survival rate and quality of life of patients. Arterial bypass has many advantages in the long-term effect, but its biggest disadvantage is that it is prone to vasospasm duri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/42A61K45/00A61K31/277A61K31/417A61K31/4422A61K31/472A61K31/495A61P9/10A61P41/00
Inventor 齐宪荣杨碧波
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap